Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 27, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 150,000 Ordinary Shares of 25 pence each.
- Purchase Date: March 27, 2013.
- Price Range: Highest price paid was 1,530.5 pence per share; lowest price paid was 1,511.5 pence per share.
- Treasury Holdings (Settled): 497,951,327 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 498,431,327 shares (10.15% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,909,439,414 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 150,000 shares. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the latest quarterly or annual report to confirm the 9.21% ownership stake.
- Confirm the total issued share capital (excluding treasury) of 4,909,439,414 shares for accurate voting rights calculations.
- Review the Annual General Meeting minutes from May 3, 2012, to understand the full scope of the share buyback authority utilized.